ArticleFrontiers in medicine2025

Correction: Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-A clinical pilot study.

Frontiers Production OfficePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.